IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype
Darya Alizadeh(CTI BioPharma (United Kingdom)), Christine E. Brown(City Of Hope National Medical Center), Ryan Urak(City of Hope), Joseph R. Pecoraro(City of Hope), Cheng-Fu Kuo(City of Hope), Xiuli Wang(City of Hope), Brenda Aguilar(City of Hope), Robyn A. Wong(City of Hope), Renate Starr(City of Hope), Yue Qi(City Of Hope National Medical Center), Dongrui Wang(Zhejiang Chinese Medical University), Xin Yang(City of Hope), Stephen J. Forman(City Of Hope National Medical Center), David K. Ann(City Of Hope National Medical Center)
Cited by 437
Related Papers
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754